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Abstract
Background: Shared decision making (SDM) implementation remains challenging. The factors that promote or
hinder implementation of SDM tools for use during the consultation, including contextual factors such as clinician
burnout and organizational support, remain unclear. We explored these factors in the context of a practical
multicenter randomized trial evaluating the effectiveness of an SDM conversation tool for patients with atrial
fibrillation considering anticoagulation therapy.
Methods: In this cross-sectional study, we recruited clinicians who were regularly involved in conversations with
patients regarding anticoagulation for atrial fibrillation. Clinicians reported their characteristics and burnout
symptoms using the two-item Maslach Burnout Inventory. Clinicians were trained in using the SDM tool, and they
recorded their perceptions of the tool’s normalization potential using the Normalization MeAsure Development
(NoMAD) survey instrument and verbally reflected on their answers to these survey questions. When possible, the
training sessions and clinicians’ verbal responses to the conversation tool were recorded.
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Results: Our study comprised 183 clinicians recruited into the trial (168 with survey responses and 112 with
recordings). Overall, clinicians gave high scores to the normalization potential of the intervention; they endorsed all
domains of normalization to the same extent, regardless of site, clinician characteristics, or burnout ratings. In
interviews, clinicians paid significant attention to making sense of the tool. Tool buy-in seemed to depend heavily
on their ability to see the tool as accurate and “evidence-based” and their perceptions of having time in the
consultation to use it.
Conclusions: While time in the consultation remains a barrier, we did not find a significant association between
burnout symptoms and normalization of an SDM conversation tool. Possible areas for improving the normalization
of SDM conversation tools in clinical practice include enabling collaboration among clinicians to implement the
tool and reporting how clinicians elsewhere use the tool. Direct measures of normalization (i.e., observing how
often clinicians access the tool in practice outside of the clinical trial) may further elucidate the role that contextual
factors, such as clinician burnout, play in the implementation of SDM.
Trial registration: ClinicalTrials.gov, NCT02905032. Registered on 9 September 2016.
Keywords: Atrial fibrillation, Shared decision making, Trials, Normalization process theory, Burnout, Anticoagulation,
Trial procedures, Conversation aid
Background
Implementing complex interventions, such as use of
shared decision making (SDM) tools, within clinical en-
counters requires participation from patients and clini-
cians. Despite evidence of their effectiveness and
enthusiastic policymaker endorsement, the real-world
uptake of tools to promote SDM has been limited [1].
Process evaluations of practical or effectiveness trials can
contribute to understanding how complex interventions,
such as use of SDM tools, may be implemented beyond
the trial period [2].
Normalization Process Theory (NPT) provides a
framework for understanding the process of implement-
ing complex interventions in healthcare [3, 4]. NPT pro-
poses that complex interventions (e.g., SDM tools in
practice) become routinely embedded (implemented and
integrated) in their organizational and professional con-
texts as a result of people working, individually and col-
lectively, to implement them. It involves four domains:
(1) making sense of the intervention, (2) getting people
involved, (3) doing the work, and (4) evaluating the
intervention in daily practice (Table 1). NPT can be used
as a framework to understand how healthcare interven-
tions interact with the existing clinic processes, clinical
practice, and patient–clinician encounters and the work
professionals do to enact them [3, 4].
Although the barriers and facilitators for the implemen-
tation of patient-facing decision aids have been reported,
less is known about the factors that promote or hinder the
implementation of SDM conversation aids, which are used
by the patient–clinician dyad during the clinical encounter
[5]. The implementation of SDM tools during the consult-
ation involves the execution and orchestration of individ-
ual and collective work and the work that is promoted or
hindered as integration into routine practice takes place.
The persistent difference between enthusiasm for SDM
and limited documented use of SDM tools in practice
strongly suggests the presence of hindering factors (e.g.,
clinician burnout, lack of organizational support, logistical
barriers). Here, we explore the factors that promote or
hinder this work within an ongoing practical randomized
trial requiring the integration of an SDM conversation
tool in practice to evaluate its effectiveness against usual
care. This SDM conversation tool, the Anticoagulation
Choice Decision Aid, was designed to assist patients with
atrial fibrillation and their clinicians with the decision of
whether and how to use anticoagulants to prevent
thromboembolic strokes [6]. We report on the participat-
ing clinicians’ characteristics and professional roles, levels
of burnout, and perspectives on normalizing the use of
the Anticoagulation Choice Decision Aid tool within the
workflow of their clinical practices.
Methods
Setting and participants
The institutional review boards of the Mayo Clinic (ap-
proval 16-005409) and two other participating sites
Table 1 Domains of Normalization Process Theory
NPT domain Focus
Coherence Making sense of the proposed intervention
Cognitive
participation
Getting people involved in the implementation
project, buy-in
Collective action Doing the work to make the intervention part
of daily practice, organizational resources, training,
and division of labor; confidence, expertise, and
intervention workability
Reflexive monitoring Evaluating the use of the intervention in daily
practice and monitoring its value
NPT Normalization Process Theory
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(Park Nicolette-HealthPartners and Hennepin Health-
care System) approved all study procedures. We re-
cruited clinicians for a randomized trial (Shared
Decision Making for Atrial Fibrillation [SDM4Afib])
evaluating the effectiveness of the Anticoagulation
Choice Decision Aid tool versus usual care in patients
with nonvalvular atrial fibrillation at risk for thrombo-
embolic strokes and considering anticoagulation (Clini-
calTrials.gov registration number NCT02905032) [7].
The tool, which can be found at anticoagulationdeci-
sionaid.mayoclinic.org, was designed to support collab-
orative conversations between patients and clinicians to
determine whether to use anticoagulation, given the pa-
tient’s risk of stroke, and how to anticoagulate (using ei-
ther warfarin or direct oral anticoagulants) based on the
relative merits (bleeding risk, dosing, need for monitor-
ing, reversibility, cost, and interactions with foods and
medications) of these options.
The SDM4Afib trial protocol [7] and the design of the
Anticoagulation Choice Decision Aid tool have been de-
scribed previously [6]. Briefly, we recruited clinicians from
three hospital sites in Minnesota: an academic medical
center, a suburban community group practice, and a safety
net health system. Clinicians were eligible if they were in-
volved in conversations about anticoagulation with pa-
tients with atrial fibrillation. Eligible clinicians were
invited to participate in the trial via e-mail and during
established clinic meetings at primary care, emergency,
cardiology, and dedicated anticoagulation practices at par-
ticipating sites. After consenting to participate in the trial,
the clinicians took part in a brief training session, either
individually or in groups. In each session, study staff dem-
onstrated how to use the Anticoagulation Choice Decision
Aid tool with a patient through role playing with the clin-
ician and, when feasible, by reviewing a brief video-
recorded demonstration. Some of these training sessions
took place “just in time” prior to appointments with eli-
gible patients (which sometimes prohibited a more exten-
sive training session with video recording), while others
were scheduled outside the time of clinical duties. The cli-
nicians were then asked to complete a questionnaire. Dur-
ing and after training sessions, participating clinicians
were invited to explore issues of normalization of the
SDM tool into their practice with prompts such as, “How
does this tool differ from your everyday work?” and “What
resources do you have for integrating this tool into prac-
tice?” Spontaneous and prompted comments made by cli-
nicians during training sessions were recorded with their
consent. Feedback and questions from training sessions
and interviews were discussed with the study principal in-
vestigators. Recommendations from those conversations
were shared with study staff via a live electronic database
and monthly in-person/phone study staff meetings (Fig. 1,
gray panel).
Statistical analysis
All quantitative analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA). We used a
chi-square test to assess the association between levels
of burnout and site (academic medical center, commu-
nity group practice, and safety net health system). We
then used analysis of covariance (ANCOVA) to investi-
gate differences between mean NoMAD domain scores
and levels of burnout and callousness, adjusting for
gender, site, years in practice, practitioner type, and spe-
cialty type (cardiology vs. other). P values < 0.05 were
considered statistically significant.
Assessing normalization: quantitative approach
The clinician questionnaire was used to collect informa-
tion about demographic and professional characteristics,
burnout symptoms, and clinicians’ perceptions of the
Anticoagulation Choice Decision Aid’s normalization
potential (Additional file 1).
Burnout was assessed using two items of the Maslach
Burnout Inventory (MBI), “I feel burned out from my
work” and “I have become more callous toward people
since I took this job,” that have strong associations with
the full MBI and key outcomes such as suicidality and
desire to drop out of training [8]. The MBI items were
scored on a 7-point scale where “never” contributed 0
points and “every day” contributed 6 points. Similar to
previously reported methods, burnout was classified as
“high,” “moderate,” or “low” [8–10]. High burnout was
classified as feeling burned out from work or feeling
more callous toward others once or more per week (4
points or greater). Medium burnout was having feelings
of burnout or callousness once or more per month but
less often than once per week (2 or 3 points). Low burn-
out was classified as feeling burned out and more callous
toward others a few times per year or less (1 point or
less).
Clinicians answered questions regarding their familiar-
ity with the tool and the Normalization Measure Devel-
opment (NoMAD) instrument after training [11].
Familiarity was rated on 10-point Likert scale anchored
by responses such as “still feels very new” and “feels
completely familiar” at the extremes. The NoMAD in-
strument elicits stakeholder views about how interven-
tions impact their work and whether the new
intervention could become normalized in their setting
by probing the four domains of NPT (Table 1) [12, 13].
In our study, we omitted questions about “reflexive
monitoring” because participants had not yet had a
chance to integrate the SDM tool into their practice.
The 15 NoMAD items, comprising 3 domains (5 items
in each), were scored on a 5-point Likert scale, where
“strongly agree” was assigned a score of 5 and “strongly
disagree” was assigned a score of 1. Psychometric testing
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of this instrument supports taking the average score for
all items within each domain [11].
Assessing normalization: qualitative approach
Training across all sites captured feedback from 112 cli-
nicians, 40 (36%) of whom received individual training
and were interviewed one-to-one. We used a computer-
generated simple random sample of 30 training record-
ings for a theory-led framework analysis. Proceedings
were transcribed and classified using inductive coding
into NPT domains (Table 1). The four coders (AT, GSB,
OJP, and PO) calibrated their judgments by analyzing
two recordings independently and successively, guided
by a preliminary codebook. Disagreements were dis-
cussed, and the codebook was iterated accordingly with
the addition of helpful examples. The remaining 28 re-
cordings were analyzed independently in pairs, with dis-
agreements discussed and resolved between reviewer
pairs or by a third coder when necessary.
Results
Table 2 reports the characteristics of 168 of the 183 en-
rolled clinicians by site with available survey data at the
time of analysis. Except for questions related to burnout,
response rates exceeded 90%. The academic medical
center had fewer female clinicians and more cardiology
specialists than the other sites, while the community
group practice clinicians were mostly family physicians
and included more clinicians in training (residents) than
the other sites. Nonresident clinicians averaged 10 to 18
years in practice. About 20% of clinicians reported feel-
ing burned out at least once per week, and 7% reported
having become more callous at least once per week since
taking their job. We found no significant associations
between these traits and practice site (P = 0.28 and 0.34,
respectively). Of these 183 clinicians who were trained
and recruited, 112 were recorded.
Normalization
In describing the possibility to integrate the SDM tool
into their practices, 168 clinicians responded to the
whole 0–10 scale with a mean of 6.6 (SD 2.5); cardiolo-
gists gave, on average, ratings that were 2 points higher.
The mean NPT domain scores were 4.1 of 5 (SD 0.5) for
coherence, 4.3 (0.5) for cognitive participation, and 3.9
(0.5) for collective action (Table 3). Using ANCOVA
Fig. 1 Normalization of Anticoagulation Choice Decision Aid tool
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adjusted for clinician characteristics, there was no sig-
nificant association between level of burnout and NPT
domain scores or sites (results not shown).
Coherence
When analyzing the recording proceedings, more than
half (60%) of the 338 clinician comments or utterances
fell within the coherence domain (i.e., understanding the
purpose and role of the tool in care). Use of the tool was
identified as differing from normal ways of working by
73% of surveyed clinicians. While they identified its vis-
ual component as an addition to their usual conversa-
tion, clinicians varied in terms of perceiving that it
would fundamentally support a different conversation.
Some clinicians stated that it was part of their obligation
to discuss all of the issues related to anticoagulation and
that they were already having this kind of conversation
“on a regular basis.” As such, some were “afraid that it
might not be much different” from what they already do.
For example, a participating clinician explained:
It’s basically a similar discussion to what I usually
have. I think the graphical representation of what I’m
discussing would be nice and probably [make it] easier.
However, 154 (92%) clinicians agreed that they “saw the
value” of using the Anticoagulation Choice Decision Aid
tool and agreed that using it was a legitimate part of
their work. They alluded to the visual aid as helpful in
their efforts to help patients understand their risk of
stroke. They also thought using the tool standardized
the conversation about anticoagulation with at-risk
patients:
The way I think about this study is that it’s not com-
paring ‘shared decision making’ to ‘no shared deci-
sion making.’ It’s comparing standard care to a
structured way of doing decision making. Because …
we have conversations with our patients every single
time, it’s just, it’s not structured, everyone does it dif-
ferently. So, we’re comparing the usual way that we
do it to using a structured tool.
Of note, this was one of only two clinician statements
among a total of 338 utterances that mentioned the term
“shared decision making.”
Cognitive participation
Many comments coded under “cognitive participation”
also pertained to “coherence” or “sense-making” work.
Common issues that came up when clinicians negotiated
“buy-in” for the tool pertained to the “risk of bleeding”
and “reversibility.” While most clinicians agreed with
statements that were consistent with high cognitive par-
ticipation, sometimes they suggested content modifica-
tions that they would want made in order to optimize
the tool for their personal use. For example, some clini-
cians questioned the accuracy of the bleeding estimates
presented, requesting more granularity in the data pre-
sented in the tool:
Table 2 Clinician characteristics
Clinician characteristics Academic medical center (n = 94) Community group practice (n = 43) Safety net system (n = 46) Total (N = 183)
Missing information (n) 12 0 3 15
Women (n, %) 32 (39) 27 (63) 24 (56) 83 (49)
Age (mean, SD) 43 (12) 41 (12) 43 (11) 43 (12)
Clinician type (n, %)
MD/DO 61 (74) 39 (91) 25 (58) 125 (74)
Resident 24 (29) 19 (44) 2 (5) 45 (27)
NP/PA 17 (21) 4 (9) 10 (23) 31 (19)
PharmD 4 (5) 0 (0) 4 (9) 8 (5)
RN 0 (0) 0 (0) 4 (9) 4 (2)
Clinician specialty (n, %)
Family medicine 2 (2) 28 (65) 0 (0) 30 (18)
Internal medicine 10 (12) 6 (14) 32 (74) 48 (29)
Cardiology 52 (64) 5 (12) 7 (16) 64 (38)
Pharmacy 4 (5) 0 (0) 0 (0) 4 (2)
Other 14 (17) 4 (9) 4 (9) 22 (13)
Years in practice (mean, SD)* 13 (10) 18 (9) 10 (10) 13 (10)
aExcludes resident physicians (physicians in training)
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I would feel OK using it for now and explaining, to
the patient, that yes, there is a bleeding risk but the
risk of intracranial hemorrhage and of dying from a
bleed is very small and is usually considered less
[than what is presented in the tool].
In some cases, clinicians suggested that their continued
use of the tool was contingent on certain modifications
to its content. For example, some requested that the tool
include information about a new reversal agent for direct
anticoagulants that was recently released. Others wanted
the tool to reflect differences they believed were import-
ant between available direct oral anticoagulants, such as
nuances in bleeding risk:
I also think that it would be important to mention
that there is one direct inhibitor that has been
shown to have less bleeding risk, you know? …
Which is apixaban, so patients need to know this
too if you’re going to be full-disclosure, evidence-
based!
Almost all clinicians were open to working with col-
leagues in new ways to use the Anticoagulation Choice
Decision Aid tool. However, 25% of clinicians surveyed
did not agree that there were “drivers” or key people in
leadership moving forward the implementation of the
SDM tool in practice. While this was seldom explicitly
mentioned by clinicians during training sessions, several
of them inquired whether specific people at their institu-
tions were participating in the trial and, unfortunately,
were largely unaware of which clinicians and depart-
ments were using the tool.
Collective action
Although most clinicians endorsed coherence and
cognitive participation, fewer endorsed statements repre-
senting collective action (i.e., having confidence in
Table 3 Normalization perceptions






Total (N = 183)
Missing (n) 12 0 3 15
SDM Integration: 1 (worst) to 10 (best); mean (SD)
Feels familiar 7.2 (2.6) 5.9 (3.0) 5.8 (2.7) 6.5 (2.8)
Currently part of normal practice 6.1 (3.6) 5.3 (3.5) 5.2 (3.2) 5.7 (3.5)
Will become part of practice 7.7 (2.3) 7.5 (2.4) 7.4 (1.9) 7.5 (2.2)
NPT domains: agree/strongly agree (n, %)
Coherence
Differs from normal work 62 (76) 30 (70) 30 (70) 122 (73)
Shared understanding by staff 68 (83) 35 (81) 33 (77) 136 (81)
Understand how SDM affects my work 67 (82) 37 (86) 40 (93) 144 (86)
I see the value 76 (93) 39 (91) 39 (91) 154 (92)
Cognitive participation
There are drivers 57 (70) 35 (81) 34 (79) 126 (75)
I believe it’s a legitimate part of work 73 (89) 39 (91) 37 (86) 149 (89)
Open to working with colleagues to improve 80 (98) 42 (98) 40 (93) 162 (96)
Will continue to support 78 (95) 39 (91) 38 (88) 155 (92)
Collective action
Easy to integrate 69 (84) 31 (72) 30 (70) 130 (77)
Disruption of working relationshipsa 9 (11) 2 (5) 2 (5) 13 (8)
Confidence in others’ abilities 58 (71) 30 (70) 29 (67) 117 (70)
Assigned to people with appropriate skills 59 (72) 35 (81) 26 (61) 120 (71)
Sufficient training 57 (70) 29 (67) 33 (77) 119 (71)
Sufficient resources 64 (78) 30 (70) 30 (70) 124 (74)
Support from management 61 (74) 33 (77) 27 (63) 121 (72)
NPT NPT Normalization Process Theory, SDM Shared decision making
aInverse coding used for items with negative framing
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others’ abilities to use Anticoagulation Choice Decision
Aid tool). Statements prompted by this question were
often vague and difficult to interpret. Consultation time,
however, was consistently and clearly described as a
scarce yet necessary resource for using the tool in prac-
tice. Particularly, the following statement shows the
interplay between collective action and cognitive partici-
pation. In this statement, the clinician alludes to time
barriers and highlights how the effort required to partici-
pate in a trial and to implement the intervention being
tested are conflated. When time was limited, especially
in the context of a research study, the tool ceased to be
a legitimate part of their daily work and instead was rele-
gated to the position of a research “add on”:
[If] the patient doesn’t show up until right on time
or whatever, we’re just gonna have to say, “Well, this
isn’t gonna work today.” So, ya know, you always
have that option, so I think we want to be good citi-
zens in the research community here, but, on the
other hand, have to balance it with our … the per-
sonal needs of the individual patients.
Comments on the “cost” also often encompassed both
collective action and cognitive participation as clinicians
negotiated whether it was their role to give patients in-
formation about the out-of-pocket cost of the available
anticoagulation strategies as the tool was designed to do.
Some identified the pharmacists as resources, while
others cited lack of pharmacists with time to provide
personalized cost information as a challenge:
I’m curious ’cause I don’t have access to that in the
ambulatory setting but the inpatient pharmacists
do.… Before they even discharge people, they give
that lovely thing that says, ‘Here’s their choices and
how much it costs.’ … Would you be able to look into
that? Or ask if that would be a resource?
Clinicians also identified a lack of environmental re-
sources for using the Anticoagulation Choice Decision
Aid tool. Besides time, they cited that the rooms they
used were not formatted so that both the clinician and
patient could share a single computer screen. They also
commented on the challenge of finding and accessing
the tool online before each use, because the computers
were shared between different healthcare professionals,




Embedding an intervention in clinical routines is neces-
sary to evaluate its effectiveness in practice. This process
takes individual and collective work subject to barriers
and facilitators. Identifying and addressing these factors
is critical in the design and implementation of practical
clinical trials. This is particularly important when bar-
riers and facilitators may differ across sites of a multisite
trial. Here, we explored the embedding of an SDM inter-
vention in routine clinical consultations as we recruited
clinicians for a multicenter trial evaluating it. Clinicians
rated the normalization potential of the intervention
highly; for cardiologists, using the SDM tool in care
made more sense than for other types of clinicians. Cli-
nicians endorsed all domains of normalization to the
same extent, regardless of site, clinician characteristics,
or burnout or callousness ratings. Ninety-two percent of
clinicians saw the value of using the Anticoagulation
Choice Decision Aid tool, and 96% were open to work-
ing with colleagues to improve the use of it in practice.
Fewer clinicians saw how the Anticoagulation Choice
Decision Aid tool differed from their normal work
(72%), agreed that there were drivers leading the imple-
mentation of the conversation aid (75%), or responded
in agreement with items related to collective action (70–
77%). Qualitatively, clinicians paid most attention to
making sense of the tool. Tool buy-in seemed to depend
heavily on clinicians’ ability to see the tool as accurate
and “evidence-based” and on their having time to use it
during consultations. They mentioned that the Anticoa-
gulation Choice Decision Aid tool might lead to
standardization of clinical encounters. Collective action
issues focused on who has time and information to use
the tool (e.g., enrolling pharmacists and the information
to which they have access when including patient out-
of-pocket costs in SDM conversations). Few clinicians
commented on the concept of “shared decision making”
per se (less than 1% of clinician utterances).
Comparison with previous studies
While clinicians found coherence between their job and
using the SDM conversation tool, they were less likely to
agree that using the Anticoagulation Choice Decision
Aid tool differed from their normal work. This is con-
sistent with a metasynthesis of qualitative studies which
found that for conversations about anticoagulation for
atrial fibrillation, clinicians reported engaging in SDM
routinely, even when patients were more likely to report
a less participatory approach [14]. This was also sup-
ported by an evaluation of real-world distribution of de-
cision aids; qualitative data suggested that clinicians did
not have a shared understanding of the purpose of the
decision aid [1].
Similar to the findings of the systematic review by
Legaré et al., who documented that clinicians identify
time constraints and lack of pertinence of the SDM
intervention to patients and clinical situations as barriers
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to SDM implementation [5]. The design of the Anticoa-
gulation Choice Decision Aid tool as an SDM conversa-
tion aid enables clinicians to tailor the tool to the
patient’s situation [6], dealing with the latter barriers,
and it may, in fact, efficiently guide a complex conversa-
tion and save time. Although SDM conversation tools de-
mand dedicated and structured work that may change the
way the clinician feels about time during the encounter, a
recent systematic review of these tools demonstrated that,
on average, these tools do not significantly prolong the
clinical encounter [15].
Previous studies have also found burnout to be nega-
tively associated with adaptive reserve [16], “practice fea-
tures that enhance resilience, such as relationships” [17].
Burnout has also been associated with less empathic
concern and decreased “effort to adopt the point of view
of another person” [18]. While SDM has been proposed
as an intervention to increase meaningful encounters
and decrease burnout [19], our findings do not directly
support an association between burnout and enthusiasm
regarding SDM. However, given the highly positive re-
sponse by clinicians to openness to collaboration with
colleagues, their multiple inquiries regarding other clini-
cians using the Anticoagulation Choice Decision Aid
tool, encouraging collaboration and innovation between
team members, and involving local leadership may im-
prove implementation of complex interventions such as
SDM tools.
Limitations
Process evaluations during trials may provide insights
about the factors that promote or inhibit the implementa-
tion of complex interventions that are different from those
gained from evaluations performed outside of research en-
deavors [2]. Research studies are temporary, require partici-
pant consent, and allow participant withdrawal without
penalties (Fig. 1). Temporary add-on trial procedures, for
instance, may overwhelm clinicians, who then opt out of
the research, or, conversely, they may elicit weaker re-
sponses than permanent or mandatory practice changes.
Similarly, clinicians choosing to participate in the trial may
have been more enthusiastic about the intervention than
those who declined. This study was conducted at the begin-
ning of the trial, before participating clinicians had an op-
portunity to use the tool with patients. Therefore, we
captured mostly clinicians’ expectations about using the
SDM tool, informed by very brief training and demonstra-
tion when clinicians may have been more enthusiastic
about the process. We did not assess “reflexive monitoring,
” the fourth domain of NPT, which requires responding to
questions after having regularly used the intervention, such
as, “Given the changes observed as a result of the interven-
tion, should we keep doing it?” For example, the organic
monitoring, appraisal, and endorsement by clinical staff
(represented by white arrows and white panel in Fig. 1)
were not measured in our study. These limitations affect in-
ferences about the normalization of SDM tools in practice
to a greater extent than about the procedures for ongoing
clinician recruitment into our trial, the purpose with which
we designed this process evaluation. Finally, while partici-
pants were informed that the results would be anonymized,
it is possible that clinicians may have felt uncomfortable
reporting high levels of burnout for fear of stigma or pro-
fessional repercussions.
Implications for research and practice
It has been suggested that SDM may decrease clinician
burnout by creating more meaningful patient–clinician
encounters [19]. A clinician communication skills train-
ing intervention was associated with a significant and
small decrease in burnout [20]. Yet, trials testing SDM
tools rarely collect the clinician perspective, with no tri-
als collecting measures of burnout or clinician well-
being [15, 19, 21]. Our study explored the interplay be-
tween SDM implementation and contextual factors such
as burnout and practice resources such as time in con-
sultation. A key insight that participants offered and de-
serves further exploration is that the normalization of
SDM tools in practice may benefit from supporting col-
lective action. We found that people were enthusiastic
about working with colleagues, a process hindered by
their lack of awareness of who else was participating in
it and who was driving the implementation of the tool in
their clinics. Perhaps future research should ascertain
not just clinician burnout but also isolation.
This process evaluation contributed to the rollout of
the trial. Clinicians were invited to provide feedback and
ask questions about trial procedures and the tool. When
study staff (research assistants and study coordinators)
were unable to answer questions in real time (e.g., about
bleeding risk estimates), questions were referred to the
principal investigators. The principal investigators, topic
experts at their own sites, contacted participating clini-
cians to respond to these queries, communicating their
buy-in in the use of the SDM tool. Internally, study staff
maintained a live database of questions and topics that
came up during clinician consent or NPT interviews.
The study staff recorded and regularly updated crowd-
sourced answers (Fig. 1) to maintain coherence regard-
ing the tool and trial within the study team and between
study sites. In these interactions, we had to maintain a
balance between facilitating the use of the SDM tool and
maintaining a sense of uncertainty about its relative effi-
cacy (rather than advocating for its value), which justi-
fied the clinical trial.
Clinicians made several requests to modify the content
of the tool. For example, the tool was designed to sup-
port a conversation between clinicians and their patients;
Spencer-Bonilla et al. Trials          (2020) 21:395 Page 8 of 10
patient and clinician expertise and experience should en-
hance the tool and tailor its effect to each patient and
situation, contributing to a pertinent and useful SDM
conversation. In this way, we resisted adding more infor-
mation to the tool, a common request, because this may
have reduced clinician participation in the conversation
and promoted instead an interaction between the patient
and the SDM tool. Other changes could be accommo-
dated. For example, we added the ability to toggle be-
tween 5-year and 1-year risk estimates.
Finally, an apparent disconnect emerged between the
communication goals of the research and of clinicians,
the former more focused on cocreation and the latter on
conveying information. A previous study showed that
even within clinic teams, there are dissimilar interpreta-
tions of SDM [22]. In our random sample of 30 record-
ings (112 clinicians), only 2 comments mentioned SDM,
and these arose from making sense of using SDM tools
rather than a philosophical discussion on the purpose of
“shared decision making.” In this way, far from having
arrived at a broad consensus of definition, purpose, and
value of SDM, our study suggests that clinicians con-
tinue to negotiate the purpose and value of SDM in their
practices. Future studies should continue to explore the
clinician perspective, particularly when SDM implemen-
tation must take place within individual and collective
workflows. Clinicians can both give meaning to SDM
tools and preclude their presence in clinical encounters.
Conclusions
We were able to use NPT to uncover potential barriers
and facilitators to the use of an SDM conversation tool
within a multicenter randomized trial evaluating its ef-
fectiveness. While most participants found SDM coher-
ent with their clinical work and expressed high levels of
buy-in, their engagement was dependent on the accuracy
of its content and the feasibility of its use within busy
clinical workflows. For some, using the SDM tool was
perceived as a peripheral add-on, perhaps a desirable
one, to their work rather than being integral to it. These
views have implications for trial procedures and arduous
implementation [23], were the trial to demonstrate that
the SDM intervention contributes to care.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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